Compare LKFN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | NRIX |
|---|---|---|
| Founded | 1872 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1997 | 2020 |
| Metric | LKFN | NRIX |
|---|---|---|
| Price | $58.27 | $16.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $67.00 | $26.50 |
| AVG Volume (30 Days) | 127.2K | ★ 1.6M |
| Earning Date | 10-27-2025 | 10-09-2025 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.79 | N/A |
| Revenue | ★ $248,271,000.00 | $83,687,000.00 |
| Revenue This Year | $17.16 | $58.48 |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $15.41 | ★ N/A |
| Revenue Growth | 2.85 | ★ 48.32 |
| 52 Week Low | $50.00 | $8.18 |
| 52 Week High | $75.64 | $23.00 |
| Indicator | LKFN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 67.18 |
| Support Level | $57.40 | $16.63 |
| Resistance Level | $59.55 | $17.79 |
| Average True Range (ATR) | 1.63 | 1.02 |
| MACD | 0.29 | 0.21 |
| Stochastic Oscillator | 57.02 | 75.17 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.